跳到正文
BiotechTV - News(podcasters.spotify.com)· BiotechTV·· 11 天前品質評分58

STIFEL 2026: ProMIS Neurosciences has an early, yet important Alzheimer's trial scheduled to read out over the coming months

STIFEL 2026: ProMIS Neurosciences has an early, yet important Alzheimer's trial scheduled to read out over the coming months

重點導讀

CEO Neil Warma describes ProMIS's approach of targeting amyloid beta oligomers as opposed to the plaques. He explains how so far they have avoided the ARIA (brain swelling) seen with other Alzheimer's treatments and discusses what the company hopes to see from this phase 1b study. Plus, comments on the recent failure of another company in this space.

AI 伴隨問答

自備 Key 深度分析

針對這篇報導有疑問?可直接點選快捷問題或向 AI 追問背景脈絡與技術細節:

Podcast 專家音訊節目

收錄於 888news Podcast 智庫專區,包含精華摘要與上市公司即時行情

正文

CEO Neil Warma describes ProMIS's approach of targeting amyloid beta oligomers as opposed to the plaques. He explains how so far they have avoided the ARIA (brain swelling) seen with other Alzheimer's treatments and discusses what the company hopes to see from this phase 1b study. Plus, comments on the recent failure of another company in this space.

來源: BiotechTV - News (podcasters.spotify.com)
開啟原文

讀者討論

理性交流 · 即時討論